On Tuesday, Piper Sandler began coverage on Upstream Bio (NASDAQ:UPB) stock, assigning an Overweight rating and setting a price target of $75.00.
The firm highlighted the potential of Upstream Bio's lead candidate, verekitug, due to its unique mechanism of action (MoA) that targets the TSLP receptor rather than the ligand. This distinction is significant as the TSLP ligand has already been validated through the 2021 approval of Tezspire for severe asthma, indicating a large and growing market.
The biologic market opportunity for treatments like verekitug is estimated to be over $7.5 billion. Verekitug has shown promise, exhibiting four times the preclinical potency compared to existing treatments and significant reductions in fractional exhaled nitric oxide (FeNO), a biomarker of airway inflammation.
These results support its development for several respiratory conditions, including severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Piper Sandler's positive outlook is further bolstered by the upcoming clinical milestones for verekitug. The ongoing Phase 2 VIBRANT trial for CRSwNP is expected to deliver top-line results in the second half of 2025, and the Phase 2 VALIANT trial in severe asthma is anticipated to follow with its top-line results in the second half of 2026. Additionally, the initiation of a Phase 2 trial for COPD is projected for the second half of 2025.
The initiation of coverage and the high price target reflect confidence in the drug's potential success and its ability to capture a significant share of the biologics market. Upstream Bio's strategic focus on developing verekitug for multiple respiratory indications could position the company to become a notable player in the treatment of these chronic conditions.
In other recent news, JPMorgan (NYSE:JPM) has initiated coverage on Upstream Bio, expressing a bullish stance on the company's stock, primarily due to the promising potential of its lead asset, verekitug.
This monoclonal antibody, developed for the treatment of severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD), is expected to be a significant driver of Upstream Bio's stock value in the medium to long term.
According to JPMorgan, phase 2 data for verekitug in treating CRSwNP is anticipated in the second half of 2025, with data for severe asthma expected in the latter half of 2026.
JPMorgan's confidence in the company is underscored by the management team's expertise and successful history in the field, as well as active strategic movements in the inflammation and immunology (I&I) sector.
The firm's analysis indicates that the progress of verekitug, particularly its advancement through the clinical trial phases and its comparison to other competitive TSLP (thymic stromal lymphopoietin) approaches, will be crucial for the stock's performance.
JPMorgan has set a price target of $38.00 for December 2025, reflecting the firm's faith in Upstream Bio's strategic direction and the anticipated success of verekitug in the coming years. These developments highlight the recent progress and future prospects of Upstream Bio.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Upstream Bio's (NASDAQ:UPB) financial position and market performance. The company's market capitalization stands at $1.35 billion, reflecting investor interest in its potential. Despite the promising outlook for verekitug, it's important to note that Upstream Bio is not currently profitable, with a negative P/E ratio of -24.59 for the last twelve months as of Q2 2024.
InvestingPro Tips highlight that Upstream Bio holds more cash than debt on its balance sheet, which could provide financial flexibility as it advances its clinical trials. Additionally, the company's liquid assets exceed short-term obligations, potentially offering a buffer for ongoing research and development expenses.
Interestingly, UPB has shown a strong return over the last month, with a 14.32% price total return. This aligns with the positive sentiment expressed in Piper Sandler's coverage initiation and could reflect growing market optimism about verekitug's potential.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights, with 6 more tips available for Upstream Bio on the platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.